LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

Home・Stock List・Sana Biotechnology Inc

Sana Biotechnology Inc

Closed

SectorHealthcare

2.68 0.37

Buy Sell

Overview

Share price change

24h

Current

Min

2.6

Max

2.71

Key metrics
By Trading Economics
Income	12M -47M
EPS	-0.171
Employees	142
EBITDA	23M -35M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+265.67% upside

Dividends
By Dow Jones
Next Earnings	7 Aug 2026

Market Stats
By TradingEconomics
Market Cap	-68M 893M
Previous open	2.31
Previous close	2.68

News Sentiment

By Acuity

25%

75%

59 / 344 Healthcare

Sana Biotechnology Inc Chart

Past performance is not a reliable indicator of future results.

Related News

8 Jun 2026, 22:20 UTC

Acquisitions, Mergers, Takeovers

Salesforce to Buy m3ter in Nod Toward AI-Native Business Models

8 Jun 2026, 15:41 UTC

Major Market Movers

American Battery Shares Jump on Energy Department Victory

8 Jun 2026, 23:46 UTC

Market Talk

Nikkei May Rebound After Monday's Selloff -- Market Talk

8 Jun 2026, 23:37 UTC

Market Talk

Oil Edges Higher Amid Ongoing Supply Disruption Concerns -- Market Talk

8 Jun 2026, 23:25 UTC

Market Talk

Should Australia Consider State-Linked Commodities Export Desk? -- Market Talk

8 Jun 2026, 23:25 UTC

Market Talk

Global Equities Roundup: Market Talk

8 Jun 2026, 21:57 UTC

Acquisitions, Mergers, Takeovers

Salesforce Expects to Close Deal in 2Q of Fiscal 2027

8 Jun 2026, 21:56 UTC

Acquisitions, Mergers, Takeovers

Salesforce Agrees to Buy m3ter

8 Jun 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

8 Jun 2026, 19:22 UTC

Market Talk

Oil Settles Higher as Israel-Iran Exchanges Raise Tension -- Market Talk

8 Jun 2026, 19:01 UTC

Market Talk

U.S. Natural Gas Futures Pull Back on Weather Outlook -- Market Talk

8 Jun 2026, 18:52 UTC

Market Talk

Global Energy Roundup: Market Talk

8 Jun 2026, 18:52 UTC

Market Talk

CAD Needs Trade Deal to Trigger Sustained Rally -- Market Talk

8 Jun 2026, 18:17 UTC

Market Talk

Oil Pulls Back Further As Iran, Israel Put Strikes on Hold -- Market Talk

8 Jun 2026, 17:32 UTC

Market Talk

Bank of Canada Should Incorporate Unemployment Rate Into Its Forecast -- Market Talk

8 Jun 2026, 17:29 UTC

Market Talk

Crypto Market Still Stays in 'Extreme Fear' Amid Rebound -- Market Talk

8 Jun 2026, 17:29 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8 Jun 2026, 16:55 UTC

Acquisitions, Mergers, Takeovers

Monte dei Paschi: Mediobanca Integration Proceeding According to Plan

8 Jun 2026, 16:54 UTC

Acquisitions, Mergers, Takeovers

Monte dei Paschi to Review Proposals From Banco BPM, Intesa Sanpaolo

8 Jun 2026, 16:40 UTC

Market Talk

Cryptocurrencies Rise After Iran and Israel Halt Exchanges of Fire -- Market Talk

8 Jun 2026, 16:31 UTC

Market Talk

No Recession in Canada, Scotiabank's CEO Says -- Market Talk

8 Jun 2026, 16:27 UTC

Market Talk

Mexican Inflation Seen Easing in May -- Market Talk

8 Jun 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8 Jun 2026, 16:03 UTC

Acquisitions, Mergers, Takeovers

Orange Bought Stake From Lorca

8 Jun 2026, 16:01 UTC

Acquisitions, Mergers, Takeovers

Orange Completes Acquisition of Remaining 50% Stake in MasOrange

8 Jun 2026, 16:01 UTC

Acquisitions, Mergers, Takeovers

Orange Acquires 100% Ownership of MasOrange

8 Jun 2026, 15:58 UTC

Market Talk

Global Equities Roundup: Market Talk

8 Jun 2026, 15:58 UTC

Market Talk

Gold Trims Losses After Israel, Iran Halt Exchanges of Fire -- Market Talk

8 Jun 2026, 15:55 UTC

Market Talk

Markets Price Small Chance USMCA Will Be Dismantled -- Market Talk

8 Jun 2026, 15:41 UTC

Market Talk

Gold Falls Below 200-Day Moving Average -- Market Talk

Peer Comparison

Price change

Sana Biotechnology Inc Forecast

Price Target

By TipRanks

265.67% upside

12 Months Forecast

Average 9.8 USD 265.67%

High 16 USD

Low 7 USD

Based on 6 Wall Street analysts offering 12 month price targets forSana Biotechnology Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

Buy

Hold

Sell

Based on 6 analysts giving stock ratings to Sana Biotechnology Inc - Dist in the past 3 months.

Sentiment

By Acuity

59 / 344 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Sana Biotechnology Inc

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.